Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00108771 · ClinicalTrials.gov registry record · Phase 2

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

A Phase 2 study of Pain, sponsored by ZARS Pharma.

Completed
Registry status
Phase 2
Development phase
202
Enrollment target
13
Study locations

NCT00108771 is a Phase 2 study of Pain that has completed, run by ZARS Pharma. The registered enrollment target is 202 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (34% lower). The trial reports 13 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00108771, a Phase 2 study of Pain, has completed, sponsored by ZARS Pharma.

COMPLETED
Registry status
Phase 2
Development phase
202 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness of the Matrix Fentanyl Patch ZR-02-01 in providing pain relief.

Conditions Studied

Interventions

  • DRUG Placebo Patch
  • DRUG ZR-02-01 Fentanyl Transdermal Matrix Patch

Study Locations (13)

California

  • Sharp Rees-Stealy Medical Group - San Diego
  • San Diego Arthritis Medical Clinic - San Diego
  • Boling Clinical Trials - Upland

Florida

  • Radiant Research - Daytona Beach
  • Ocala Rheumatology - Ocala
  • Tampa Medical Group - Tampa

Arizona

  • Arizona Reserach Center - Phoenix
  • Redpoint Research - Phoenix

Massachusetts

  • Pain Trials Center - Brigham & Women's Hospital - Boston
  • Phase III Clinical Trials - Fall River

New York

  • Beth Israel Medical Center - New York
  • Analgesic Development Ltd. - New York

Louisiana

  • New Orleans Center for Clinical Research - New Orleans

Trial Details

FieldValue
Enrollment Target 202 participants
Start Date 2004-04
Est. Completion 2006-09
Phase Phase 2

Sponsor

ZARS Pharma

23 total trials

What the Registry Record Tells You About NCT00108771

The ClinicalTrials.gov registry entry for NCT00108771 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (34% lower). The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo Patch is the first listed.

NCT00108771 reports 13 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00108771 about?

NCT00108771 is a clinical study titled "Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain". The purpose of this study is to evaluate the effectiveness of the Matrix Fentanyl Patch ZR-02-01 in providing pain relief.

What is the current status of trial NCT00108771?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2004-04. Estimated completion is 2006-09.

What conditions does trial NCT00108771 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT00108771?

The interventions under investigation include: Placebo Patch (DRUG), ZR-02-01 Fentanyl Transdermal Matrix Patch (DRUG).

Who is sponsoring clinical trial NCT00108771?

This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00108771 being conducted?

This trial has 13 study locations across Arizona, California, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.